HOPEWELL, N.J., August 4, 2021 — Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced that management will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually from August 10-11, 2021. The details are as follows:
Event: 2021 Wedbush PacGrow Healthcare Conference
Panel: So Let it Be (Re)Written – Updates in Gene Modulation
Date: Tuesday, August 10, 2021
Time: 9:10 AM ET
Members of the Gennao Bio management team will also host investor meetings during the conference.
A live webcast of the panel discussion will be available on the company’s website at www.gennao.com. A replay of the webcast will also be available for 30 days shortly after the conclusion of the event.
About Gennao Bio
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.